Micromet has licensed out one of its BiTE anticancer antibodies to Sanofi-aventis in a deal that is worth up to US$477 M if all milestones are achieved. Micromet’s BiTE® (Bispecific T Cell Engager) is a novel therapeutic approach for treating cancer.